 Connection
William Robinson to Dacarbazine
This is a "connection" page, showing publications William Robinson has written about Dacarbazine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.217 |
|
|
|
-
Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer. 1994; 22(3):233-45.
Score: 0.108
-
Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012 Oct; 30(10):2100-13.
Score: 0.025
-
Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
Score: 0.024
-
Kirkwood JM, Ernstoff MS, Giuliano A, Gams R, Robinson WA, Costanzi J, Pouillart P, Speyer J, Grimm M, Spiegel R. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
Score: 0.021
-
Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
Score: 0.016
-
Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
Score: 0.015
-
Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol. 1995 Dec; 18(6):488-90.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|